Biosimulation Market Report Scope & Overview:

The Biosimulation Market Size was valued at USD 2.4 billion in 2023 and is expected to reach USD 8.4 billion by 2031, and grow at a CAGR of 17.0% over the forecast period 2024-2031.

The inclination of researchers towards biosimulation is expected to be stimulated by technological innovations and periodic updates in the software. It is likely that the market will be stimulated significantly. The adoption of microarrays and predictive models is one such technological advance. Semantic technologies which allow for a limited number of biosimulation elements to be supported, thereby reducing the time, cost and complexity of the whole process are also emerging. In addition, an urgent need for developing stronger and more sophisticated medicines growing the market. In the simulation of diseases such as diabetes mellitus, biosimulation is increasingly used. For the development of models for next generation drugs, it uses proteomics and genomic technologies.

Biosimulation-Market Revenue Analysis

Get more information on Biosimulation Market - Request Sample Report



  • In the biotechnology and pharmaceutical sector, expenditure on research and development is increasing

  • Increasing the use of biosimulation software among regulators

  • Expansion in the biologics and biosimilars market.

The global biosimilars market is experiencing growth primarily propelled by several factors, including the increasing pressure to reduce healthcare costs, rising demand for cost-effective biosimilars, higher prevalence of diseases, growing availability of off-patent drugs, favorable results from ongoing clinical trials, and escalating demand for biosimilars across various therapeutic applications like rheumatoid arthritis and blood disorders. Pharmaceutical companies are trying to find new uses for existing medicines as the research and development of new chemical entities has not been very successful. Biosimulation technologies are used to confirm the hypothesis of the use of these medicinal products for a new indication or disease, since toxicity and other essential parameters of drug safety have already been tested.


  • Lack of standardization

To capture and process different aspects of biochemical processes, biosimulation uses a range of models, tools and languages. In order to facilitate the creation, reuse, composition and merging of various biosimulation models with each other, existing modelling methods do not capture the underlying semantics of these model types. In the area of drug discovery and development, there is still a lack of standardisation between regulatory bodies on use of in silico or biosimulation technology.


  • There has been an increase in the use of personalised medicines.

  • The use of biosimulation methods in the development of paediatric medicinal products

  • Emerging applications

Significant opportunities for growth of the global biosimulation market are emerging in areas such as defense, industrial bioprocessing, nutraceuticals and agriculture. In order to expand the application of their biosimulation software and services, different biosimulation companies adopt a strategy of inorganic growth strategies.


  • It is difficult to compare the complexity of biological systems and processes.

  • The shortage of biosimulation and modelling experts

Biosimulation is a method of representing the actual life processes that take place in human bodies by means of mathematics equations. Scientists can simulate a wide range of scenarios and study the behaviour of human systems in various situations because they are able to replicate biological elements and their interactions with drugs when introduced into our system. However, to operate, plan and monitor biosimulation software, skills are needed. There is a high demand for scientists who are well acquainted with biosimulation methods, e.g. Molecular Model Simulation and PKPD modeling and simulation at research laboratories and businesses.

Impact of Russia-Ukraine War

Due to their roles as major producers of pharmaceutical raw materials and active ingredients, both countries are expected to have a negative impact on the supply chain. Any interruption, for example transport blockades or export restrictions, could result in shortages of essential components which would affect production and distribution around the world. In addition, due to supply chain disruption and currency fluctuations, the conflict could lead to higher costs for businesses. Profit margins and financial performance could be affected by the higher prices for basic materials, transport and logistics. The potential for political instability to create regulatory uncertainty, there may also be regulatory challenges. The ability of companies to bring their products into the markets effectively could be hampered by delays in approving new medicinal products or clinical trials, together with changing regulations on imports and exports.

Impact of Economic slowdown

The biosimulation market have been varying effects of the current economic slowdown. The market for biosimulation, driven by factors such as the increasing adoption of biosimulation software, the need to reduce drug discovery and development costs and the increase in research and development activities of pharmaceutical and biotechnology companies, has shown resilience and continued growth despite the economic downturn. In addition, when companies reassess their portfolios and focus on more promising or less risky opportunities, a downturn in the economy may result in delayed or canceled drug development projects. As these tools are used to optimise drug development and predict the efficacy and safety of new medicinal products, this may have a direct effect on demand for biosimulation services. The FDA's endorsement of biosimulation in research and development, as well as the growing use of artificial intelligence tools and technology for drug discovery and development that are expected to stimulate a wider adoption of biosimulation is also having an impact on the market.

Market Segmentation

By Product

  • Software

  • Services

  • In-house Services

  • Contract Services

In 2023, software accounted for more than 68.9% of the market's revenue. This is because there are a large number of Application Specific Software available on the market that cater to special R&D requirements. For example, Rhenovia Pharma provides software that specializes in simulation of the mechanism of CNS specific drugs. Software and services are part of the product segment.

By Delivery Model

  • Subscription Models

  • Ownership Models

By Application

  • Drug Development

  • Drug Discovery

  • Others

In 2023, drug development accounted for the largest revenue share of more than 59.8%. The growth of this segment is driven by an increasing number of government initiatives encouraging the use of advanced software. For example, the importance of this approach to developing drugs is highlighted in a report from the FDA on its Critical Path initiative and suggests that it can be incorporated as an effective predictive tool. Development of drugs, drug discovery and other areas are covered by the application segment.

By End-use

  • Pharmaceutical & Biotechnology Companies

  • CROs

  • Regulatory Authorities

  • Academic Research Institutions

In 2023, the revenue share of pharmaceutical and biotechnology companies was over 54.3% due to continuous efforts by key companies to prolong the life cycle of off patent drugs and to discover novel drug variants through the use of computer models can be attributed to the strong demand for biosimulation in these companies. The end user segment is composed of pharmaceutical and biotechnology companies, contract research organizations, regulators as well as academic research institutions.

Regional Analysis

In 2023, North America had the largest revenue share of more than 49.7%. The presence of key stakeholders, increased digitisation in healthcare and the growing incidence of health problems are factors contributing to this growth. In addition, it also contributes to the growth of this region's market by adopting insilico models when enforcing legislation with a view to ensuring safe and efficient treatment for patients.

The Asia Pacific is expected to grow at a compound annual growth rate of 18.5% over the forecast period, driven by growing public and private sector initiatives as well as constant improvements in health infrastructure. Moreover, the region is set to benefit from significant growth opportunities due to rapidly expanding research and development activities of developing economies.


​​​​​​​Need any customization research on the Biosimulation Market - Enquiry Now


North America

  • US

  • Canada

  • Mexico


  • Eastern Europe

    • Poland

    • Romania

    • Hungary

    • Turkey

    • Rest of Eastern Europe

  • Western Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Netherlands

    • Switzerland

    • Austria

    • Rest of Western Europe

Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Vietnam

  • Singapore

  • Australia

  • Rest of Asia Pacific

Middle East & Africa

  • Middle East

    • UAE

    • Egypt

    • Saudi Arabia

    • Qatar

    • Rest of the Middle East

  • Africa

    • Nigeria

    • South Africa

    • Rest of Africa

Latin America

  • Brazil

  • Argentina

  • Colombia

  • Rest of Latin America


Some of the major key players are Advanced Chemistry Development, BioSimulation Consulting Inc., Certara, Dassault Systemes, Genedata AG, Chemical Computing Group ULC, Simulation Plus, Physiomics Plc, Rosa & Co. LLC, Schrodinger, Inc. and other players.

Advanced Chemistry Development-Company Financial Analysis

Company Landscape Analysis


Recent Developments:

  • In June 2022, Certara has unveiled an updated version of its Biosimulation software tailored for advancing Novel Biologics. This new version integrates Immunogenicity (IG), Immuno-Oncology (IO), and Vaccine simulators, enabling users to comprehend and forecast drug mechanisms and identify pivotal queries in the progression of innovative biologic therapies.

  • In June 2022, Genedata AG announced that in order to speed up its Translational Research Strategy, Syros Pharmaceuticals has selected the Genedata Profiler as a Data Integration and Investigation Platform.

  • In March 2022, Advanced Chemistry Laboratories announced that Pharmaron Inc. had chosen its software to process and interpret the NMR data.

Biosimulation Market Report Scope:
Report Attributes Details
Market Size in 2023  US$ 2.4 Billion
Market Size by 2031  US$ 8.4 Billion
CAGR  CAGR of 17% From 2024 to 2031
Base Year   2023
Forecast Period  2024-2031
Historical Data  2020-2022
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Product (Software, Services)
• By Delivery Model (Subscription Models, Ownership Models)
• By Application (Drug Development, Drug Discovery, Others)
• By End-Use (Pharmaceutical & Biotechnology Companies, CROs, Regulatory Authorities, Academic Research Institutions)
Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America)
Company Profiles Advanced Chemistry Development, BioSimulation Consulting Inc., Certara, Dassault Systemes, Genedata AG, Chemical Computing Group ULC, Simulation Plus, Physiomics Plc, Rosa & Co. LLC, Schrodinger, Inc.
Key Drivers • Rise in R&D expenditures in the biotechnology and pharmaceutical sectors
• Increasing regulatory bodies' use of biosimulation software
• QSP Systems with the Latest Technology
Restraints • Absence of Standards

Frequently Asked Questions

Ans: The Biosimulation Market size was valued at US$ 2.4 billion in 2023

Ans: The Biosimulation Market is growing at a CAGR of 17% over the forecast period 2024-2031

 The COVID-19 pandemic had a major effect on the healthcare sector, which included the biosimulation business. The requirement for quick testing and development of COVID-19 vaccine candidates sparked a demand for biosimulation tools and services.

The market is divided in four segments by Product & Service, By Application, By Delivery Model, and By End User 

Ans. Emerging Technologies, and Use of personalised medicine has increased are the opportunities of the Biosimulation ma


1. Introduction

1.1 Market Definition

1.2 Scope

1.3 Research Assumptions

2. Industry Flowchart

3. Research Methodology

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

5. Impact Analysis

5.1 Impact of Russia-Ukraine Crisis

5.2 Impact of Economic Slowdown on Major Countries

5.2.1 Introduction

5.2.2 United States

5.2.3 Canada

5.2.4 Germany

5.2.5 France

5.2.6 UK

5.2.7 China

5.2.8 Japan

5.2.9 South Korea

5.2.10 India

6. Value Chain Analysis

7. Porter’s 5 Forces Model

8.  Pest Analysis

9. Biosimulation Market Segmentation, by Product

9.1 Introduction

9.2 Trend Analysis

9.3 Software

9.4 Services

9.4.1 In-house Services

9.4.2 Contract Services

10. Biosimulation Market Segmentation, by Delivery Model 
10.1 Introduction
10.3 Trend Analysis
10.4 Subscription Models
10.5 Ownership Models

11. Biosimulation Market Segmentation, by Application
11.1 Introduction
11.3 Trend Analysis
11.4 Drug Development
11.5 Drug Discovery
11.6 Others

12. Biosimulation Market Segmentation, by End-use

12.1 Introduction

12.2 Trend Analysis

12.3 Pharmaceutical & Biotechnology Companies

12.4 CROs

12.5 Regulatory Authorities

12.6 Academic Research Institutions

13. Regional Analysis

13.1 Introduction

13.2 North America

13.2.1 USA

13.2.2 Canada

13.2.3 Mexico

13.3 Europe

13.3.1 Eastern Europe Poland Romania Hungary Turkey Rest of Eastern Europe

13.3.2 Western Europe Germany France UK Italy Spain Netherlands Switzerland Austria Rest of Western Europe

13.4 Asia-Pacific

13.4.1 China

13.4.2 India

13.4.3 Japan

13.4.4 South Korea

13.4.5 Vietnam

13.4.6 Singapore

13.4.7 Australia

13.4.8 Rest of Asia Pacific

13.5 The Middle East & Africa

13.5.1 Middle East UAE Egypt Saudi Arabia Qatar Rest of the Middle East

13.5.2 Africa Nigeria South Africa Rest of Africa

13.6 Latin America

13.6.1 Brazil

12.6.2 Argentina

13.6.3 Colombia

13.6.4 Rest of Latin America

14. Company Profiles

14.1 Advanced Chemistry Development

14.1.1 Company Overview

14.1.2 Financial

14.1.3 Products/ Services Offered

14.1.4 SWOT Analysis

14.1.5 The SNS View

14.2 BioSimulation Consulting Inc.

14.2.1 Company Overview

14.2.2 Financial

14.2.3 Products/ Services Offered

14.2.4 SWOT Analysis

14.2.5 The SNS View

14.3 Certara

14.3.1 Company Overview

14.3.2 Financial

14.3.3 Products/ Services Offered

14.3.4 SWOT Analysis

14.3.5 The SNS View

14.4 Dassault Systemes

14.4.1 Company Overview

14.4.2 Financial

14.4.3 Products/ Services Offered

14.4.4 SWOT Analysis

14.4.5 The SNS View

14.5 Genedata AG

14.5.1 Company Overview

14.5.2 Financial

14.5.3 Products/ Services Offered

14.5.4 SWOT Analysis

14.5.5 The SNS View

14.6 Chemical Computing Group ULC

14.6.1 Company Overview

14.6.2 Financial

14.6.3 Products/ Services Offered

14.6.4 SWOT Analysis

14.6.5 The SNS View

14.7 Simulation Plus

14.7.1 Company Overview

14.7.2 Financial

14.7.3 Products/ Services Offered

14.7.4 SWOT Analysis

14.7.5 The SNS View

14.8 Physiomics Plc

14.8.1 Company Overview

14.8.2 Financial

14.8.3 Products/ Services Offered

14.8.4 SWOT Analysis

14.8.5 The SNS View

14.9 Rosa & Co. LLC

14.9.1 Company Overview

14.9.2 Financial

14.9.3 Products/ Services Offered

14.9.4 SWOT Analysis

14.9.5 The SNS View

14.10 Schrodinger, Inc

14.10.1 Company Overview

14.10.2 Financial

14.10.3 Products/ Services Offered

14.10.4 SWOT Analysis

14.10.5 The SNS View

15. Competitive Landscape

15.1 Competitive Benchmarking

15.2 Market Share Analysis

15.3 Recent Developments

15.3.1 Industry News

15.3.2 Company News

15.3.3 Mergers & Acquisitions

16. Use Case and Best Practices

17. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.


The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone